Engineered cells take on Hard-to-Treat liver cancer
NCT ID NCT07487402
First seen Mar 23, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This early-phase trial tests a new treatment called Meta10-GPC3 for people with advanced liver cancer that cannot be removed by surgery. The treatment uses specially modified immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check safety, and the study will also look at whether tumors shrink. About 27 adults whose tumors have a specific marker (GPC3) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.